Hepatocellular carcinoma(HCC)is a critical cancerworldwide due to its low survival rate[1].In the United States,the overall 5-year survival rate of patients with HCC is 22%,which decreases sharply with cancer progress...Hepatocellular carcinoma(HCC)is a critical cancerworldwide due to its low survival rate[1].In the United States,the overall 5-year survival rate of patients with HCC is 22%,which decreases sharply with cancer progression[2].Early detection of HCC improves patient survival.Serum alpha-fetoprotein(AFP)is a widely used biomarker for the diagnosis of HCC,but it is often elevated in patients with cirrhosis,resulting in false-positive results[3].Diagnostic markers for early detection of HCC have been investigated previously[4],but none are widely applied in clinical settings.展开更多
基金the National Research Foundation of Korea(NRF)funded by the Ministry of Science,ICT,and Future Planning(NRF-2020R1C1C1007431,NRF-2022R1A2C1003118,RS-2024-00341766,RS-2025-00514590,NRF-2021R1A5A2021614)the Korean Fund for Regenerative Medicine(KFRM)grant funded by the Korean government(the Ministry of Science and ICT,the Ministry of Health&Welfare,21A0404L1)the KRIBB Research Initiative Program.
文摘Hepatocellular carcinoma(HCC)is a critical cancerworldwide due to its low survival rate[1].In the United States,the overall 5-year survival rate of patients with HCC is 22%,which decreases sharply with cancer progression[2].Early detection of HCC improves patient survival.Serum alpha-fetoprotein(AFP)is a widely used biomarker for the diagnosis of HCC,but it is often elevated in patients with cirrhosis,resulting in false-positive results[3].Diagnostic markers for early detection of HCC have been investigated previously[4],but none are widely applied in clinical settings.
